Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients
Abstract
Rationale Brain-derived neurotrophic factor (BDNF) is a neurotrophin that plays a major role in neurogenesis and neuroplasticity, and in the modulation of several neurotransmitter systems including the dopaminergic system. There are mixed reports about the association between the BDNF Val66Met polymorphism, schizophrenia, and treatment response to antipsychotic drugs.Objectives The present study evaluated the association of the BDNF Val66Met polymorphism with treatment response to atypical antipsychotic olanzapine in schizophrenia and the possible predictive value of the BDNF Val66Met genotype status in treatment response to antipsychotic medication.Methods The study included 590 ethnically homogenous Caucasian patients with schizophrenia (diagnosed using the SCID), 40.2 ± 12.0 years old, treated with olanzapine monotherapy (10-20 mg/day), or with other antipsychotics such as risperidone (3-6 mg/day), clozapine (100-500 mg/day), haloperidol (3-115 mg/day), fluphenazine (4-25 mg/day), and quetiapine (50-800 mg/day). Patients were subdivided into responders and non-responders according to a 50 % reduction in the Positive and Negative Syndrome Scale (PANSS) total and subscale scores after 8 weeks of treatment.Results The results, corrected for possible effects of gender and age, showed a significant association between the BDNF Val66Met polymorphism and treatment response to olanzapine in patients. The Val/Val genotype was observed more frequently in treatment responders to olanzapine, and this genotype was associated with an improvement in clinical symptoms.Conclusions Our results suggest that BDNF Val66Met variants might influence the response to 8 weeks of monotherapy with olanzapine, in a relatively large sample of patients with schizophrenia.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some studies suggest that baseline BDNF levels in schizophrenia patients might reflect the susceptibility towards available drug therapies.
“In addition, some studies suggest that baseline BDNF levels in schizophrenia patients might reflect the susceptibility towards available drug therapies [129, 130].”
From Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation (2019) · cites this paper as [130]
Cites
A simple salting out procedure for extracting DNA from human nucleated cells
Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.3.1215 · Cited by 20,341 · see citing works
Effect size estimates: Current use, calculations, and interpretation.
Fritz, C. O., Morris, P. E., & Richler, J. J. (2012) · Journal of Experimental Psychology: General · doi:10.1037/a0024338 · Cited by 5,199 · cited 1× · see citing works
“For data analyzed by Mann–Whitney tests, the Z value was used to calculate effect size (r) (Fritz et al. 2012).”
Applied Nonparametric Statistics
Wozniak, P. J., & Daniel, W. W. (1991) · Technometrics · doi:10.2307/1268795 · Cited by 5,008 · see citing works
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · see citing works
Binder (2004) · doi:10.1080/08977190410001723308 · Cited by 1,481 · see citing works
Chen, Z.-Y., Patel, P. D., Sant, G., Meng, C.-X., Teng, K. K., Hempstead, B. L., & Lee, F. S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0348-04.2004 · Cited by 874 · see citing works
Neurotrophin signalling in health and disease
Chao, M. V., Rajagopal, R., & Lee, F. S. (2006) · Clinical Science · doi:10.1042/cs20050163 · Cited by 619 · see citing works
BDNF in schizophrenia, depression and corresponding animal models
Angelucci, F., Brené, S., & Mathé, A. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001637 · Cited by 548 · see citing works
Meta-analysis: Its strengths and limitations
WALKER, E., HERNANDEZ, A. V., & KATTAN, M. W. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75.6.431 · Cited by 519 · see citing works
Applied Nonparametric Statistics.
Streitberg, B., & Daniel, W. W. (1991) · Biometrics · doi:10.2307/2532422 · Cited by 505 · see citing works
Gratacòs, M., González, J. R., Mercader, J. M., de Cid, R., Urretavizcaya, M., & Estivill, X. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.08.025 · Cited by 428 · see citing works
Sartorius, A., Hellweg, R., Litzke, J., Vogt, M., Dormann, C., Vollmayr, B., Danker-Hopfe, H., & Gass, P. (2009) · Pharmacopsychiatry · doi:10.1055/s-0029-1224162 · Cited by 276 · see citing works
Neurotrophic factors and structural plasticity in addiction
Russo, S. J., Mazei‐Robison, M. S., Ables, J. L., & Nestler, E. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.059 · Cited by 271 · see citing works
Population genetic study of the brain-derived neurotrophic factor (BDNF) gene
Petryshen, T. L., Sabeti, P. C., Aldinger, K. A., Fry, B., Fan, J. B., Schaffner, S. F., Waggoner, S. G., Tahl, A. R., & Sklar, P. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.24 · Cited by 267 · see citing works
Leucht, S., Davis, J. M., Engel, R. R., Kane, J. M., & Wagenpfeil, S. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301325 · Cited by 216 · see citing works
BDNF and Schizophrenia: From Neurodevelopment to Neuronal Plasticity, Learning, and Memory
Nieto, R. R., Manuel Kukuljan, P., & Silva, H. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00045 · Cited by 213 · see citing works
Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction
Zhang, J., & Malhotra, A. K. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2011.532787 · Cited by 195 · see citing works
Suzuki, T., Remington, G. J., Mulsant, B. H., Uchida, H., Rajji, T. K., Graff‐Guerrero, A., Mimura, M., & Mamo, D. C. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.013 · Cited by 177 · see citing works
Neurotrophins and schizophrenia
Buckley, P. F., Mahadik, S. P., Pillai, A., & Terry, A. V. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.01.025 · Cited by 166 · see citing works
Lang, U. E., Hellweg, R., Seifert, F. C., Schubert, F., & Gallinat, J. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.002 · Cited by 156 · see citing works
Hong, C., Yu, Y. W. ‐., Lin, C., & Tsai, S. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00828-0 · Cited by 144 · see citing works
The Role of Neurotrophins in Neurotransmitter Release
Tyler, W. J., Perrett, S. P., & Pozzo‐Miller, L. D. (2002) · The Neuroscientist · doi:10.1177/1073858402238511 · Cited by 140 · see citing works
Basic Statistics: Tales of Distributions.
Kleber, R. S., Spatz, C., & Johnston, J. O. (1977) · Journal of the American Statistical Association · doi:10.2307/2286246 · Cited by 140 · see citing works
Decreased BDNF in patients with antipsychotic naïve first episode schizophrenia
Jindal, R. D., Pillai, A. K., Mahadik, S. P., Eklund, K., Montrose, D. M., & Keshavan, M. S. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2009.12.035 · Cited by 122 · see citing works
Effects of BDNF polymorphisms on brain function and behavior in health and disease
Hong, C., Liou, Y., & Tsai, S. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.08.019 · Cited by 118 · see citing works
Russo‐Neustadt, A. A. (2003) · Seminars in Clinical Neuropsychiatry · doi:10.1053/scnp.2003.50014 · Cited by 111 · see citing works
Pivac, N., Kim, B., Erjavec, G. N., Joo, Y. H., Kozarić‐Kovačić, D., Hong, J. P., & Mück‐Šeler, D. (2009) · Croatian Medical Journal · doi:10.3325/cmj.2009.50.43 · Cited by 110 · see citing works
Self-citationPutative neuroprotective agents in neuropsychiatric disorders
Dodd, S., Maes, M. H. J., Anderson, G., Dean, O. M., Moylan, S., & Berk, M. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.11.007 · Cited by 105 · see citing works
Neurotrophic factors and the maldevelopmental hypothesis of schizophrenic psychoses
Thome, J., Foley, P., & Riederer, P. F. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050040 · Cited by 101 · see citing works
BDNF Val66Met is Associated with Introversion and Interacts with 5-HTTLPR to Influence Neuroticism
Terracciano, A., Tanaka, T., Sutin, A. R., Deiana, B., Balaci, L., Sanna, S., Olla, N., Maschio, A., Uda, M., Ferrucci, L., et al. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.213 · Cited by 94 · see citing works
Is the PANSS used correctly? a systematic review
Obermeier, M., Schennach-Wolff, R., Meyer, S., Möller, H., Riedel, M. J., Krause, D., & Seemüller, F. (2011) · BMC Psychiatry · doi:10.1186/1471-244x-11-113 · Cited by 83 · see citing works
A Review of Brain-derived Neurotrophic Factor as a Candidate Biomarker in Schizophrenia
Nurjono, M., Lee, J., & Chong, S. A. (2012) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2012.10.2.61 · Cited by 75 · see citing works
Zai, G. C., Zai, C. C. H., Chowdhury, N. I., Tiwari, A. K., de Souza, R. P., Lieberman, J. A., Meltzer, H. Y., Potkin, S. G., Müller, D. J., & Kennedy, J. L. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.05.014 · Cited by 73 · see citing works
Pae, C.-U., Chiesa, A., Porcelli, S., Han, C., Patkar, A. A., Lee, S.-J., Park, M. H., Serretti, A., & Ronchi, D. D. (2011) · Neuropsychobiology · doi:10.1159/000327605 · Cited by 67 · see citing works
Pharmacotherapy for treatment-resistant schizophrenia
Harrison, J., McIlwain, M., Wheeler, A., & Russell (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s12769 · Cited by 67 · see citing works
Zhang, J., Lencz, T., Geisler, S., DeRosse, P., Bromet, E. J., & Malhotra, A. K. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.020 · Cited by 66 · see citing works
BDNF is not associated with schizophrenia: Data from a Japanese population study and meta-analysis
Kawashima, K., Ikeda, M., Kishi, T., et al. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.03.040 · Cited by 59 · see citing works
Lee, J. G., Cho, H. Y., Park, S. W., Seo, M. K., & Kim, Y. H. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.05.013 · Cited by 56 · see citing works
Anttila, S., Illi, A., Kampman, O., Mattila, K. M., Lehtimäki, T. J., & Leinonen, E. V. J. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0233-9 · Cited by 52 · see citing works
Brain-derived neurotrophic factor Val66Met polymorphism and alcohol-related phenotypes
Erjavec, G. N., Perković, M. N., Šviglin, K. N., Mück‐Šeler, D., Borovečki, F., & Pivac, N. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.09.005 · Cited by 49 · see citing works
Self-citationXu, M., Clair, D. S., Feng, G., Lin, Z., He, G., Li, X., & He, L. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f85e26 · Cited by 44 · see citing works
Xu, M., Li, S., Xing, Q., Gao, R., Feng, G., Lin, Z., Clair, D. S., & He, L. (2010) · European Journal of Human Genetics · doi:10.1038/ejhg.2009.238 · Cited by 39 · see citing works
Pivac, N., Perković, M. N., Erjavec, G. N., Mustapić, M., Borovečki, F., Hajnšek, S., Presečki, P., Pavlović, M., Mimica, N., & Šeler, D. M. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.10.020 · Cited by 36 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Brain-Derived Neurotrophic Factor in Brain Disorders: Focus on Neuroinflammation
Lima Giacobbo, B., Doorduin, J., Klein, H. C., Dierckx, R. A. J. O., Bromberg, E., & de Vries, E. F. J. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1283-6 · Cited by 750 · see citing works
Harrisberger, F., Smieskova, R., Schmidt, A., Lenz, C., Walter, A., Wittfeld, K., Grabe, H. J., Lang, U. E., Fusar-Poli, P., & Borgwardt, S. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.04.017 · Cited by 138 · see citing works
Kudlek Mikulic, S., Mihaljevic-Peles, A., Sagud, M., Bajs Janovic, M., Ganoci, L., Grubisin, J., Kuzman Rojnic, M., Vuksan Cusa, B., Bradaš, Z., & Božina, N. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2017.1340518 · Cited by 25 · see citing works
- Authors
- Nikolac Perkovic, M., Nedic Erjavec, G., Zivkovic, M., Sagud, M., Uzun, S., Mihaljevic-Peles, A., Kozumplik, O., Muck-Seler, D., & Pivac, N.
- Affiliations
- Klinika za psihijatriju Vrapče (HR)
- Ruđer Bošković Institute (HR)
- Corresponding author
- Pivac, Nela
- Venue
- Psychopharmacology
- Published
- 2014-03-05
- Volume
- 231
- Issue
- 18
- Pages
- 3757-3764
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W1986427543
- Cited by
- 35
- References
- 43
- Citations by year
- 2024: 5 · 2023: 1 · 2021: 2 · 2020: 1 · 2019: 2 · 2018: 6 · 2017: 5 · 2016: 4 · 2015: 6 · 2014: 3
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repository of the Ruđer Bošković Institute (Ruđer Bošković Institute) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- brain-derived neurotrophic factor, BDNF Val66Met polymorphism, olanzapine, schizophrenia, antipsychotic treatment response, atypical antipsychotics, genetic predictors of treatment response, PANSS
- MeSH terms
- Olanzapine, Adult, Benzodiazepines, Clozapine, Female, Genotype, Haloperidol, Humans, Male, Middle Aged, Pharmacogenetics, Predictive Value of Tests, Schizophrenia, Antipsychotic Agents, Treatment Outcome, Risperidone, Brain-Derived Neurotrophic Factor, Polymorphism, Single Nucleotide, Genetic Association Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
